electroCore, Inc. Q4 2025 Earnings Call Summary

electroCore, Inc. Q4 2025 Earnings Call Summary - Moby

Strategic Performance and Operational Context

Revenue growth of 27% for full year 2025 was driven by continued penetration of the VA hospital system and a 93% surge in Truvaga wellness sales. The VA channel remains the primary revenue driver, currently reaching approximately 13,400 patients, which management estimates is only 2% of the addressable VA headache market. Strategic shift in the direct-to-consumer segment toward the company's own e-commerce site improved Return on Advertising Spend (ROAS) to $2.10 in Q4. The acquisition of Quell assets in May 2025 contributed $1.5 million in revenue, successfully diversifying the product portfolio within the VA system. Management attributes the 31% year-over-year Q4 revenue growth to increased 'boots on the ground' through a mix of internal staff and variable-cost 1099 representatives. Operational efficiency remains a core focus, with gross margins reaching 87% as the company scales its high-margin non-invasive vagus nerve stimulation (nVNS) platform.

Invest in Gold

American Hartford Gold: #1 Precious Metals Dealer in the Nation Learn More

Thor Metals Group: Best Overall Gold IRA Learn More

Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Learn More

Powered by Money.com - Yahoo may earn commission from the links above.

Outlook and Strategic Initiatives

Full year 2026 revenue is projected to grow at approximately 30%, though formal detailed guidance is paused pending the permanent CEO search. The appointment of Michael Fox as COO in April 2026 is intended to leverage his 30 years of experience to accelerate penetration into federal healthcare systems. The company plans to launch 'Quell Relief' for lower extremity pain in the first half of 2026, targeting the over-the-counter market as an incremental revenue stream. Strategic focus for 2026 includes establishing Kaiser Permanente as a 'beachhead' managed care account to demonstrate clinical and cost-saving value to other private insurers. Development of a next-generation mobile application is underway to provide a personalized user experience and support future recurring revenue opportunities.

Leadership Transition and Risk Factors

CEO Daniel Goldberger will retire effective April 1, 2026, with CFO Joshua Lev serving as Interim President during the Board's search for a successor. A one-time $500,000 order for a third-party clinical trial in Q3 2025 created a sequential flat-revenue appearance for Truvaga, which otherwise grew 40%. Operating expenses increased by $7 million in 2025, primarily due to a $3.8 million rise in variable sales and marketing costs directly tied to revenue growth. The company maintains a cash position of $11.6 million as of December 31, 2025, to fund its path toward profitability.

Q&A Highlights

Growth strategy for VA and DTC channels in 2026

Growth in the VA will be driven by the new COO's federal channel expertise and an expanded network of 1099 sales representatives. DTC growth will focus on high-efficiency media spend and expanding affiliate partnerships, such as the recent Miranda Kerr collaboration.

Story Continues

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Status of international markets and NHS England

NHS England remains the primary international revenue driver, though growth is currently limited by specific physician prescribing bottlenecks. Management is developing 'adjudication infrastructure' in other regions like Belgium through third-party distributors before committing to further expansion.

Impact of CEO departure on TAC-STIM military business

Management clarified there will be no de-emphasis on TAC-STIM; the new COO’s experience with 'the Hill' and federal systems may actually help accelerate this 'lumpy' business.

Sustainability of Return on Advertising Spend (ROAS) targets

The company aims to maintain a ROAS between $2.00 and $2.50 for 2026 by dynamically shifting media dollars to the most efficient channels. While they have previously seen ROAS exceed $3.00, they view $2.00 as a sustainable and conservative baseline for the wellness segment.

Barriers to broader commercial insurance reimbursement

The primary strategy is securing success within the Kaiser system first, which management believes will act as a catalyst for other managed care providers in 2027 and 2028.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

View Comments